3.4.21.27	drug development	activated factor XI inhibition as a viable method to increase the ratio of benefit to risk in an antithrombotic drug	707308	
3.4.21.27	medicine	anti-thrombosis therapy	669420	
3.4.21.27	medicine	antithrombosis therapy	667059	
3.4.21.27	medicine	blood coagulation	667620	
3.4.21.27	medicine	diagnosis of FXI deficiency may be considered in patients with delayed postoperative bleeding and prolonged activated partial thromboplastin time, especially in a demographically high-risk population, such as Ashkenazi Jews. Women with severe FXI deficiency and prolonged activated partial thromboplastin time can be managed with fresh frozen plasma transfusion before neuraxial anesthesia	707134	
3.4.21.27	medicine	the enzyme may be a suitable target for the development of an antithrombotic therapy	683756	
3.4.21.27	medicine	therapeutically targeting FXI may offer a strategy for preventing or treating arterial thrombosis that is not associated with the high rate of hemorrhage that accompanies many currently used anticoagulants. Pharmacological FXI inhibitors may be beneficial in septic disease	709722	
3.4.21.27	medicine	treatment options for FXI-deficient patients include virus-inactivated fresh frozen plasma, plasma-derived FXI concentrates, and activated recombinant FVII. Potential role of desmopressin for either treatment of bleeding episodes or the prevention of postoperative bleeding in patients with milder FXI defects. A single desmopressin infusion is sufficient to provide an efficient perioperative hemostasis	707148